2024 American College of Cardiology (Atlanta)

LBCT Presentation

Brian Bergmark – Efficacy And Safety Of Olezarsen In Patients With Hypertriglyceridemia And High Cardiovascular Risk: Primary Results Of The BRIDGE-TIMI 73a Trial

Other Presentations

Samer Al Said – Identification Of Atrial Fibrillation Patients With Favorable Outcomes On Warfarin: An Individual Patient-Level Analysis Of 29,272 Warfarin Patients From The COMBINE-AF Study

Samer Al Said – Long-Term Evolocumab in Elderly Patients With Established Atherosclerotic Cardiovascular Disease – An Analysis from FOURIER and FOURIER-OLE

Rohan Bajaj – Concurrent Evaluation Of HSTNI And HSTNT And Their Associations With Cardiovascular Events In 37,886 Patients With Stable Atherosclerotic Cardiovascular Disease

David Berg – Cardiogenic Shock Epidemiology In Cardiac Intensive Care Units (CICUS) Using The Framework Of The Shock Academic Research Consortium (SHARC) Consensus Definitions

Robert Giugliano – Should Frail Elderly AF Patients On VKA Switch To A DOAC? A Randomized Comparison From COMBINE-AF, A Patient-Level Metanalysis Of The 4 Large RCTS Of DOACs VS Warfarin

Paul Haller – Soluble Suppression Of Tumorigenicity 2 (SST2) And Cardiovascular Outcomes In Persons With Type 2 Diabetes Mellitus Randomized To Dapagliflozin Or Placebo: Analyses From The DECLARE-TIMI 58 Trial

Danny McClintick – Use Of Palliative Care Services In Patients With Cardiogenic Shock: Insights From The Critical Care Cardiology Trials Network (CCCTN) Registry

Andre Nicolau – Frailty Status And Outcomes In 58,634 Patients With Atrial Fibrillation Randomized To DOAC VS Warfarin

Siddharth Patel – Early Changes In Aggregate Vasoactive Support And Mortality In Cardiogenic Shock: Insights From The Critical Care Cardiology Trials Network Registry

Siddharth Patel – SGLT2 Inhibitors And Major Adverse Cardiovascular Events In Patients With Diabetes At High Risk For Atherosclerotic Cardiovascular Disease, Heart Failure Or Chronic Kidney Disease: A SMART-C Collaborative Meta-Analysis

Andre Zimerman – Effect Of DOACs Versus Warfarin By ASCVD Status In 58,634 Patients With Atrial Fibrillation: A Pooled Analysis Of 4 Randomized Trials

Andre Zimerman – Cardiovascular Benefit Of Evolocumab In 27,564 Patients With And Without Autoimmune Or Inflammatory Diseases: An Analysis Of The FOURIER Trial